Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims

被引:12
|
作者
Weycker, Derek [1 ]
Hanau, Ahuva [1 ]
Lonshteyn, Alexander [1 ]
Bowers, Charles [2 ]
Bensink, Mark [2 ]
Garawin, Tamer [2 ]
Chandler, David [2 ]
机构
[1] Policy Anal Inc PAI, Four Davis Court, Brookline, MA 02445 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
Febrile neutropenia; pegfilgrastim; granulocyte colony-stimulating factor; RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY; SINGLE-ADMINISTRATION PEGFILGRASTIM; COLONY-STIMULATING FACTORS; US CLINICAL-PRACTICE; BREAST-CANCER; DOUBLE-BLIND; DAILY FILGRASTIM; DOSE-INTENSITY; PHASE-III; MULTICENTER;
D O I
10.1080/03007995.2018.1495621
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Two recent evaluations reported that risk of febrile neutropenia (FN) may be higher when pegfilgrastim prophylaxis (PP) is administered on same day as chemotherapy rather than per recommendation (1-3 days following chemotherapy). Such evidence is based largely on the experience of younger privately insured adults and may not be generalizable to older patients in US clinical practice. Methods: A retrospective cohort design and data from Medicare Claims Research Identifiable Files (January 2008-September 2015) were employed. Patients were aged >= 65 years, had breast cancer or non-Hodgkin's lymphoma, received chemotherapy with intermediate/high risk for FN, and received PP in >= 1 cycle; cycles with PP were stratified based on administration day (same-day ["Day 0"] vs. 1-3 days following chemotherapy ["Days 1-3"]) and were pooled for analyses. Adjusted odds ratios (ORs) for FN during the cycle were estimated for patients who received PP on Day 0 versus Days 1-3. Results: Study population included 65,003 patients who received PP in 261,184 cycles; in 5% of cycles, patients received PP on Day 0. Incidence proportion for FN in cycle 1 was 11.4% for Day 0 versus 8.4% for Days 1-3; adjusted OR was 1.4 (p < .001). Incidence proportion for FN when considering all cycles was 7.7% for Day 0 and 6.0% for Days 1-3; adjusted OR was 1.3 (p < .001). Adjusted ORs when considering all cycles and only inpatient FN episodes (1.3, p < .001) and the narrow definition for FN (1.5, p < .001) were similar. Conclusions: Among Medicare patients receiving chemotherapy and PP in US clinical practice, PP was administered before the recommended timing in 5% of cycles and FN incidence was significantly higher in these cycles. Along with prior research, study findings support recently updated US practice guidelines indicating that PP should be administered the day after chemotherapy.
引用
收藏
页码:1705 / 1711
页数:7
相关论文
共 13 条
  • [1] Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims
    Weycker, Derek
    Hanau, Ahuva
    Lonshteyn, Alexander
    Bowers, Charles
    Garawin, Tamer
    Bensink, Mark
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (04) : 725 - 730
  • [2] Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015
    Weycker, Derek
    Bensink, Mark
    Lonshteyn, Alexander
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2107 - 2113
  • [3] A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI
    Eckstrom, John
    Bartels, Trace
    Abraham, Ivo
    Patel, Hitendra
    Elquza, Emad
    Scott, Aaron J.
    Malangone, Steven
    Hollings, Jerrelee
    McBride, Ali
    SUPPORTIVE CARE IN CANCER, 2019, 27 (03) : 873 - 878
  • [4] Efficacy and safety of same-day versus next-day administration of PEG-rhG-CSF for the prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia in patients with breast cancer: a retrospective cohort study
    Zhang, Yu-Fei
    Zhang, Rou-Mei
    Gu, Wen-Xin
    Jin, Yi-Ting
    Ma, Chun-Lai
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, : 2147 - 2154
  • [5] Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy
    Kitchen, Kyle
    Mosier, Michael C.
    FUTURE ONCOLOGY, 2022, 18 (23) : 2551 - 2560
  • [6] The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review
    Lyman, Gary H.
    Allcott, Kim
    Garcia, Jacob
    Stryker, Scott
    Li, Yanli
    Reiner, Maureen T.
    Weycker, Derek
    SUPPORTIVE CARE IN CANCER, 2017, 25 (08) : 2619 - 2629
  • [7] Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis
    Hobbs, Jacob
    Lowe, Jan
    Ferdinand, Abigale
    Shook, Anna
    Beck, Bradley
    Blais, Danielle
    Borchardt, Cole
    Xu, Bing
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (08) : 1853 - 1861
  • [8] Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy
    McBride, Ali
    Alrawashdh, Neda
    Bartels, Trace
    Moore, Logan
    Persky, Daniel
    Abraham, Ivo
    FUTURE ONCOLOGY, 2021, 17 (26) : 3485 - 3497
  • [9] A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI
    John Eckstrom
    Trace Bartels
    Ivo Abraham
    Hitendra Patel
    Emad Elquza
    Aaron J Scott
    Steven Malangone
    Jerrelee Hollings
    Ali McBride
    Supportive Care in Cancer, 2019, 27 : 873 - 878
  • [10] The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review
    Gary H. Lyman
    Kim Allcott
    Jacob Garcia
    Scott Stryker
    Yanli Li
    Maureen T. Reiner
    Derek Weycker
    Supportive Care in Cancer, 2017, 25 : 2619 - 2629